Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (SBCC)

GlobeNewswireJan 8 09:50 ET

Biofrontera Inc. Announces 100 RhodoLED XL Machines Now Placed in US Market

GlobeNewswireDec 23, 2024 09:30 ET

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

GlobeNewswireNov 22, 2024 09:10 ET

10-Q: Q3 2024 Earnings Report

SECNov 14, 2024 11:34 ET · Announcements

8-K: Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

SECNov 13, 2024 17:23 ET

Express News | Biofrontera Inc - Data Now Being Analyzed, Interim Results Expected November 2024

ReutersOct 14, 2024 10:30 ET